Kovitz Investment Group Partners LLC Acquires New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Kovitz Investment Group Partners LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 267 shares of the biopharmaceutical company’s stock, valued at approximately $220,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Norges Bank purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $697,296,000. Capital International Investors boosted its holdings in Regeneron Pharmaceuticals by 37.3% during the second quarter. Capital International Investors now owns 2,956,615 shares of the biopharmaceutical company’s stock worth $2,124,326,000 after purchasing an additional 803,143 shares during the last quarter. Moneta Group Investment Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 57,848.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 582,384 shares of the biopharmaceutical company’s stock worth $420,184,000 after purchasing an additional 581,379 shares during the last quarter. Bank of Montreal Can purchased a new position in Regeneron Pharmaceuticals during the second quarter worth about $116,520,000. Finally, Virginia Retirement Systems ET AL purchased a new position in Regeneron Pharmaceuticals during the second quarter worth about $83,318,000. 84.15% of the stock is owned by institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 827 shares of the stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,325,338. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $817.30, for a total value of $81,730.00. Following the completion of the sale, the director now directly owns 18,447 shares of the company’s stock, valued at approximately $15,076,733.10. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the sale, the director now directly owns 1,382 shares of the company’s stock, valued at $1,325,338. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,911 shares of company stock valued at $10,781,770. Insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $953.42 on Monday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $973.99. The company’s fifty day moving average price is $900.23 and its 200-day moving average price is $842.29. The firm has a market capitalization of $103.88 billion, a price-to-earnings ratio of 27.44, a PEG ratio of 2.76 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last released its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same quarter last year, the firm earned $10.96 EPS. The firm’s quarterly revenue was up .6% compared to the same quarter last year. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.53 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of research analyst reports. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 5th. Truist Financial reiterated a “buy” rating and issued a $1,045.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, December 18th. TD Cowen boosted their target price on shares of Regeneron Pharmaceuticals from $900.00 to $1,000.00 and gave the company an “outperform” rating in a research note on Wednesday, December 6th. Jefferies Financial Group upped their price target on shares of Regeneron Pharmaceuticals from $935.00 to $937.00 and gave the company a “buy” rating in a research note on Tuesday, November 28th. Finally, Royal Bank of Canada upped their price target on shares of Regeneron Pharmaceuticals from $1,076.00 to $1,110.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $939.05.

Check Out Our Latest Stock Report on REGN

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Recommended Stories

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.